Friday, May 22, 2015 Last update: 10:03 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Alimera Sciences, Inc.

News articles for Alimera Sciences, Inc.:

Monday, May 18, 2015

Monday, May 11, 2015

  • Alimera Sciences To Present At UBS Global Healthcare Conference
    ATLANTA, May 11, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its management will present at the UBS Global Healthcare Conference in New York. Dan Myers, President and ... read more

Thursday, May 7, 2015

  • Alimera Sciences Reports First Quarter 2015 Financial Results
    ATLANTA, May 7, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2015. Dan Myers, president and chief executive officer of Alimera commented, "We launched ... read more

Tuesday, April 28, 2015

  • Alimera Sciences to Release First Quarter 2015 Financial Results
    ATLANTA, April 28, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter 2015 financial results after the market close on Thursday, May 7, ... read more

Tuesday, April 14, 2015

Thursday, March 19, 2015

Wednesday, March 4, 2015

  • Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results
    ATLANTA, March 4, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and year ended December 31, 2014. "This past year was ... read more

Monday, February 23, 2015

  • Alimera Sciences To Release Fourth Quarter And Fiscal Year 2014 Financial Results
    ATLANTA, Feb. 23, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2014 financial results after the market close on ... read more
  • Alimera Sciences To Present At 2015 Cowen Healthcare Conference
    ATLANTA, Feb. 23, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will present at the 2015 Cowen Healthcare Conference ... read more

Tuesday, February 17, 2015

  • Alimera Sciences To Host ILUVIEN® Live Webinar Launch Event
    ATLANTA, Feb. 17, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced it will host a live webinar for eye care professionals on Monday, March 2, 2015, at 8:30 p.m. EST, during which ... read more

Monday, January 26, 2015

Wednesday, January 14, 2015

  • Alimera Sciences Announces First Sale of ILUVIEN® in Portugal
    ATLANTA, Jan. 14, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals today announced that the first unit of ILUVIEN(®) has been sold in Portugal for the treatment of vision impairment associated with ... read more

Tuesday, December 16, 2014

  • Alimera Sciences Added to NASDAQ Biotechnology Index
    ATLANTA, Dec. 16, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ Biotechnology Index ... read more

Monday, December 15, 2014

Monday, December 1, 2014

Friday, November 28, 2014